Ophthalmology papers
Pofolia’s corpus holds 49 papers from Ophthalmology (2012–2026), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis (2014, 5,326 citations).
- The 20 papers listed have 41,236 citations between them.
- 19 of the 20 with a known journal quartile appeared in a Q1 journal.
- 12 have a free full text (open access).
- Most frequent journals: JAMA Ophthalmology, New England Journal of Medicine, Progress in Retinal and Eye Research.
- Published between 2012 and 2021.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
The Lancet Global Health · 2014 · Q1 · SJR 5.00 · FWCI 35.91 · 5,326 citations
This meta-analysis estimates that 8.69% of individuals aged 45-85 have age-related macular degeneration (AMD), with projections indicating the number of affected people will rise from 196 million in 2020 to 288 million by 2040.
Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy
Cellular Physiology and Biochemistry · 2017 · Q3 · FWCI 363.11 · 5,140 citations · Open access
Anti-VEGF drugs Aflibercept and Ranibizumab protect retinal pigment epithelium (RPE) cells from oxidative damage by increasing nitric oxide (NO) release and modulating autophagy pathways.
Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Diabetes Care · 2012 · Q1 · SJR 7.00 · FWCI 115.75 · 4,940 citations · Open access
Diabetic retinopathy (DR) affects 34.6% of people with diabetes globally, with 10.2% experiencing vision-threatening DR (VTDR). These conditions are significantly linked to longer diabetes duration and poorer glycemic and blood pressure control.
The Pathophysiology and Treatment of Glaucoma
JAMA · 2014 · Q1 · SJR 5.00 · FWCI 90.11 · 4,103 citations
Glaucoma, a leading cause of irreversible vision loss, is characterized by progressive optic nerve damage, often linked to intraocular pressure. Reducing intraocular pressure is the only proven treatment method.
Optical coherence tomography angiography
Progress in Retinal and Eye Research · 2017 · Q1 · SJR 5.00 · FWCI 84.02 · 1,740 citations · Open access
Optical coherence tomography angiography (OCTA) is a decade-old imaging technology that provides unprecedented, depth-resolved visualization of retinal and choroidal blood flow, surpassing older methods.
Retinal Vascular Layers Imaged by Fluorescein Angiography and Optical Coherence Tomography Angiography
JAMA Ophthalmology · 2014 · Q1 · SJR 2.00 · FWCI 111.68 · 1,615 citations
Optical coherence tomography (OCT) angiography successfully visualized the radial peripapillary capillary network, a feat not achieved by conventional fluorescein angiography in 12 healthy eyes.
Diabetic Retinopathy
New England Journal of Medicine · 2012 · Q1 · SJR 18.00 · FWCI 63.94 · 1,600 citations
Despite rising diabetes rates, diabetic retinopathy incidence is declining, likely due to improved management of glucose, lipids, and blood pressure.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
New England Journal of Medicine · 2015 · Q1 · SJR 18.00 · FWCI 150.72 · 1,586 citations · Open access
Intravitreous aflibercept, bevacizumab, and ranibizumab all improved vision in patients with diabetic macular edema, but aflibercept showed greater efficacy only in eyes with worse baseline visual acuity.
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Eye and Vision · 2015 · Q1 · SJR 1.00 · FWCI 60.23 · 1,580 citations · Open access
Diabetic retinopathy (DR) affects about one-third of the estimated 285 million people with diabetes globally, with a third of those cases being vision-threatening, including diabetic macular edema (DME).
The Lancet Global Health Commission on Global Eye Health: vision beyond 2020
The Lancet Global Health · 2021 · Q1 · SJR 5.00 · FWCI 171.45 · 1,543 citations · Open access
Improving global eye health is a cost-effective strategy that unlocks human potential and directly contributes to achieving multiple Sustainable Development Goals, including poverty reduction, improved productivity, and better general health.
The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria
Journal of the European Academy of Dermatology and Venereology · 2013 · Q1 · SJR 2.00 · FWCI 45.56 · 1,462 citations
New International Criteria for Behçet's Disease (ICBD) demonstrate significantly improved sensitivity (94.8%) compared to existing criteria (85.0%), while maintaining reasonable specificity (90.5%). These criteria were developed using data from 2556 patients and 1163 controls across 27 countries.
The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age‐Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults
Oxidative Medicine and Cellular Longevity · 2016 · Q1 · SJR 1.00 · FWCI 88.19 · 1,452 citations · Open access
Reactive oxygen species (ROS) are implicated in the pathogenesis of numerous adult eye diseases, including corneal dystrophies, glaucoma, optic neuropathies, cataracts, and age-related macular degeneration.
Diabetic Retinopathy: Pathophysiology and Treatments
International Journal of Molecular Sciences · 2018 · Q1 · SJR 1.00 · FWCI 62.61 · 1,363 citations · Open access
Diabetic retinopathy (DR), a common diabetes complication, involves more than just microvascular damage, with inflammation and neurodegeneration also contributing significantly to retinal damage.
Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China
JAMA Ophthalmology · 2020 · Q1 · SJR 2.00 · FWCI 185.86 · 1,284 citations · Open access
Approximately one-third (31.6%) of COVID-19 patients exhibited ocular manifestations like conjunctivitis, and a small percentage (5.2%) showed SARS-CoV-2 presence in conjunctival swabs.
Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection
Journal of Medical Virology · 2020 · Q1 · SJR 1.00 · FWCI 171.00 · 1,149 citations
SARS-CoV-2 RNA was detected in tear and conjunctival secretions from one out of 30 patients with COVID-19, specifically in the single patient who presented with conjunctivitis.
A review of optical coherence tomography angiography (OCTA)
International Journal of Retina and Vitreous · 2015 · Q1 · SJR 1.00 · FWCI 68.34 · 1,132 citations · Open access
Optical coherence tomography angiography (OCTA) is a novel, non-invasive imaging technique that rapidly produces volumetric angiographic images, offering detailed structural and blood flow information for retinal vascular diseases.
Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
Ophthalmology · 2014 · Q1 · SJR 3.00 · FWCI 82.36 · 1,117 citations
A three-year trial found that dexamethasone intravitreal implants (Ozurdex) at both 0.7 mg and 0.35 mg doses significantly improved visual acuity and reduced retinal thickness in patients with diabetic macular edema compared to sham treatment.
Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review
Clinical and Experimental Ophthalmology · 2015 · Q1 · SJR 1.00 · FWCI 26.74 · 1,074 citations · Open access
Diabetic retinopathy (DR) is a major global cause of vision loss, with rising diabetes incidence posing significant public health and cost challenges for screening programs.
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
JCI Insight · 2017 · Q1 · SJR 2.00 · FWCI 57.27 · 1,051 citations · Open access
Diabetic retinopathy (DR) is a leading cause of vision loss, and while treatments for its severe forms have improved, new therapies are needed to address the complex interplay of vascular, glial, and neuronal damage in the diabetic retina.
Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis
Progress in Retinal and Eye Research · 2015 · Q1 · SJR 5.00 · FWCI 53.75 · 979 citations
A novel hypothesis suggests inappropriate activation of the mineralocorticoid pathway, involving the KCa2.3 channel in choroidal vessels, underlies central serous chorioretinopathy (CSCR) and its comorbidities.
Recently added
Few-shot neuromorphic vision in a nonlinear photonic network laser
Science Advances · 2026 · Q1 · SJR 4.00 · FWCI 8.65 · 2 citations
A retinally inspired photonic computing system using a random network laser achieves 98.05% accuracy on MNIST and outperforms software CNNs in few-shot learning scenarios.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 107.65 · 888 citations · Open access
Tebentafusp significantly improved 1-year overall survival by 14% (73% vs. 59%) in previously untreated metastatic uveal melanoma patients compared to investigator's choice of therapy (pembrolizumab, ipilimumab, or dacarbazine) in a Phase 3 trial (n=378).
The Lancet Global Health Commission on Global Eye Health: vision beyond 2020
The Lancet Global Health · 2021 · Q1 · SJR 5.00 · FWCI 171.45 · 1,543 citations · Open access
Improving global eye health is a cost-effective strategy that unlocks human potential and directly contributes to achieving multiple Sustainable Development Goals, including poverty reduction, improved productivity, and better general health.
Glaucoma in Adults—Screening, Diagnosis, and Management
JAMA · 2021 · Q1 · SJR 5.00 · FWCI 72.07 · 682 citations
Glaucoma, a leading cause of irreversible blindness, can be managed by recognizing systemic risk factors and medications that predispose patients to the condition, enabling timely referral for ophthalmologic examination.
Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China
JAMA Ophthalmology · 2020 · Q1 · SJR 2.00 · FWCI 185.86 · 1,284 citations · Open access
Approximately one-third (31.6%) of COVID-19 patients exhibited ocular manifestations like conjunctivitis, and a small percentage (5.2%) showed SARS-CoV-2 presence in conjunctival swabs.
Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals
Ocular Immunology and Inflammation · 2020 · Q2 · FWCI 99.50 · 716 citations
Coronaviruses (CoVs), including SARS-CoV-2, may infect ocular tissues, with documented animal CoV infections causing conjunctivitis, uveitis, retinitis, and optic neuritis.
Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection
Journal of Medical Virology · 2020 · Q1 · SJR 1.00 · FWCI 171.00 · 1,149 citations
SARS-CoV-2 RNA was detected in tear and conjunctival secretions from one out of 30 patients with COVID-19, specifically in the single patient who presented with conjunctivitis.
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data
Ophthalmology · 2019 · Q1 · SJR 3.00 · FWCI 57.08 · 803 citations
An international panel of experts established a consensus nomenclature for reporting neovascular age-related macular degeneration (AMD) data, defining subtypes and consequences of the disease.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 4 | 376 |
| Progress in Retinal and Eye Research | Q1 | 5.00 | 215 | 4 | 4 |
| Ophthalmology | Q1 | 3.00 | 309 | 4 | 5 |
| JAMA Ophthalmology | Q1 | 2.00 | 235 | 4 | 5 |
| Diabetes Care | Q1 | 7.00 | 449 | 3 | 27 |
| JAMA | Q1 | 5.00 | 818 | 3 | 114 |
| The Lancet Global Health | Q1 | 5.00 | 168 | 2 | 19 |
| Proceedings of the National Academy of Sciences of the United States of America | Q1 | 3.00 | 929 | 2 | 110 |
Every journal in Ophthalmology (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app